Cargando…

Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study

BACKGROUND: Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate the nature and extent of “gaps” between best-practice and current-practice care, specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Strawbridge, Rebecca, McCrone, Paul, Ulrichsen, Andrea, Zahn, Roland, Eberhard, Jonas, Wasserman, Danuta, Brambilla, Paolo, Schiena, Giandomenico, Hegerl, Ulrich, Balazs, Judit, Caldas de Almeida, Jose, Antunes, Ana, Baltzis, Spyridon, Carli, Vladmir, Quoidbach, Vinciane, Boyer, Patrice, Young, Allan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280921/
https://www.ncbi.nlm.nih.gov/pubmed/35703080
http://dx.doi.org/10.1192/j.eurpsy.2022.28
_version_ 1784746759287734272
author Strawbridge, Rebecca
McCrone, Paul
Ulrichsen, Andrea
Zahn, Roland
Eberhard, Jonas
Wasserman, Danuta
Brambilla, Paolo
Schiena, Giandomenico
Hegerl, Ulrich
Balazs, Judit
Caldas de Almeida, Jose
Antunes, Ana
Baltzis, Spyridon
Carli, Vladmir
Quoidbach, Vinciane
Boyer, Patrice
Young, Allan H.
author_facet Strawbridge, Rebecca
McCrone, Paul
Ulrichsen, Andrea
Zahn, Roland
Eberhard, Jonas
Wasserman, Danuta
Brambilla, Paolo
Schiena, Giandomenico
Hegerl, Ulrich
Balazs, Judit
Caldas de Almeida, Jose
Antunes, Ana
Baltzis, Spyridon
Carli, Vladmir
Quoidbach, Vinciane
Boyer, Patrice
Young, Allan H.
author_sort Strawbridge, Rebecca
collection PubMed
description BACKGROUND: Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate the nature and extent of “gaps” between best-practice and current-practice care, specifically to: 1. Identify current treatment gaps along the care pathway and determine the extent of these gaps in comparison with the stepped-care model and 2. Recommend policies intending to better meet patient needs (i.e., minimize treatment gaps). METHODS: After agreement upon a set of relevant treatment gaps, data pertaining to each gap were gathered and synthesized from several sources across six European countries. Subsequently, a modified Delphi approach was undertaken to attain consensus among an expert panel on proposed recommendations for minimizing treatment gaps. RESULTS: Four recommendations were made to increase the depression diagnosis rate (from ~50% episodes), aiming to both increase the number of patients seeking help, and the likelihood of a practitioner to correctly detect depression. These should reduce time to treatment (from ~1 to ~8 years after illness onset) and increase rates of treatment; nine further recommendations aimed to increase rates of treatment (from ~25 to ~50% of patients currently treated), mainly focused on targeting the best treatment to each patient. To improve follow-up after treatment initiation (from ~30 to ~65% followed up within 3 months), seven recommendations focused on increasing continuity of care. For those not responding, 10 recommendations focused on ensuring access to more specialist care (currently at rates of ~5–25% of patients). CONCLUSIONS: The treatment gaps in depression care are substantial and concerning, from the proportion of people not entering care pathways to those stagnating in primary care with impairing and persistent illness. A wide range of recommendations can be made to enhance care throughout the pathway.
format Online
Article
Text
id pubmed-9280921
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-92809212022-07-29 Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study Strawbridge, Rebecca McCrone, Paul Ulrichsen, Andrea Zahn, Roland Eberhard, Jonas Wasserman, Danuta Brambilla, Paolo Schiena, Giandomenico Hegerl, Ulrich Balazs, Judit Caldas de Almeida, Jose Antunes, Ana Baltzis, Spyridon Carli, Vladmir Quoidbach, Vinciane Boyer, Patrice Young, Allan H. Eur Psychiatry Research Article BACKGROUND: Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate the nature and extent of “gaps” between best-practice and current-practice care, specifically to: 1. Identify current treatment gaps along the care pathway and determine the extent of these gaps in comparison with the stepped-care model and 2. Recommend policies intending to better meet patient needs (i.e., minimize treatment gaps). METHODS: After agreement upon a set of relevant treatment gaps, data pertaining to each gap were gathered and synthesized from several sources across six European countries. Subsequently, a modified Delphi approach was undertaken to attain consensus among an expert panel on proposed recommendations for minimizing treatment gaps. RESULTS: Four recommendations were made to increase the depression diagnosis rate (from ~50% episodes), aiming to both increase the number of patients seeking help, and the likelihood of a practitioner to correctly detect depression. These should reduce time to treatment (from ~1 to ~8 years after illness onset) and increase rates of treatment; nine further recommendations aimed to increase rates of treatment (from ~25 to ~50% of patients currently treated), mainly focused on targeting the best treatment to each patient. To improve follow-up after treatment initiation (from ~30 to ~65% followed up within 3 months), seven recommendations focused on increasing continuity of care. For those not responding, 10 recommendations focused on ensuring access to more specialist care (currently at rates of ~5–25% of patients). CONCLUSIONS: The treatment gaps in depression care are substantial and concerning, from the proportion of people not entering care pathways to those stagnating in primary care with impairing and persistent illness. A wide range of recommendations can be made to enhance care throughout the pathway. Cambridge University Press 2022-06-15 /pmc/articles/PMC9280921/ /pubmed/35703080 http://dx.doi.org/10.1192/j.eurpsy.2022.28 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Research Article
Strawbridge, Rebecca
McCrone, Paul
Ulrichsen, Andrea
Zahn, Roland
Eberhard, Jonas
Wasserman, Danuta
Brambilla, Paolo
Schiena, Giandomenico
Hegerl, Ulrich
Balazs, Judit
Caldas de Almeida, Jose
Antunes, Ana
Baltzis, Spyridon
Carli, Vladmir
Quoidbach, Vinciane
Boyer, Patrice
Young, Allan H.
Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
title Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
title_full Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
title_fullStr Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
title_full_unstemmed Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
title_short Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
title_sort care pathways for people with major depressive disorder: a european brain council value of treatment study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280921/
https://www.ncbi.nlm.nih.gov/pubmed/35703080
http://dx.doi.org/10.1192/j.eurpsy.2022.28
work_keys_str_mv AT strawbridgerebecca carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT mccronepaul carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT ulrichsenandrea carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT zahnroland carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT eberhardjonas carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT wassermandanuta carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT brambillapaolo carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT schienagiandomenico carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT hegerlulrich carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT balazsjudit carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT caldasdealmeidajose carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT antunesana carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT baltzisspyridon carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT carlivladmir carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT quoidbachvinciane carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT boyerpatrice carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy
AT youngallanh carepathwaysforpeoplewithmajordepressivedisorderaeuropeanbraincouncilvalueoftreatmentstudy